Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US. Proveca has been granted a non-exclusive option to license Cessatech’s CT002 program. Proveca is a global pharmaceutical company specialising in the development and licensing of…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.